Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
about
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsDaptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococciComparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolidImpact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci.Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs PatientsTrends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.Multicenter study of high-dose daptomycin for treatment of enterococcal infectionsA current perspective on daptomycin for the clinical microbiologist.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes.Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus.
P2860
Q26752922-00E65F0E-C79D-466B-A0E7-17B208DCEC73Q26851754-73C0D18F-F3BF-4D9A-B7C5-D7FA5B8AA04DQ33703519-444F047D-B643-4299-97F6-083D22037732Q33798444-3423F0A2-46DB-4047-BD87-670AA1061B36Q35802607-2470C862-985C-4989-B46A-56A4B14EBC00Q35999714-333ADBFA-0FDD-4BA8-9A10-20FFDDB078EAQ36018925-DA56B7FB-BA2B-4D36-80E4-8CE3023A38B6Q36373724-9B592A9D-7B09-40C5-8043-A348C2FC0A23Q37124177-F8AA345D-8AC6-48C1-9811-E069FFAEB585Q37263289-F3C1DBDB-944C-4CCB-9CB4-382EAF9767C9Q38263421-E19DC8D2-72B1-4FF7-9909-D83A07B6431DQ38325502-E22C4D92-BC18-468C-B01D-527FE83A115FQ38347869-07A73C8C-99D3-44EB-8F07-6B0FB861E02AQ40254524-63979EFC-CB85-407E-93E7-7F3BB51A11A9Q41696975-4B7254DD-424B-4A95-B757-1E1259A6F758
P2860
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
@en
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
@nl
type
label
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
@en
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
@nl
prefLabel
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
@en
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
@nl
P2093
P356
P1476
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
@en
P2093
Dorothy McCoy
Esther A King
Keri Bicking
Samit Desai
Themba Nyirenda
P304
P356
10.1093/JAC/DKR255
P407
P577
2011-06-22T00:00:00Z